Table 1. Patient Characteristicsa.
| Characteristic | Patients With OCSCC (N = 6900) |
||
|---|---|---|---|
| CRT (n = 2091) |
S+PORT (n = 4809) |
Effect Size, % (95% CI) | |
| Median follow-up, mo | 17.3 (9.0-38.8) | 25.6 (12.9-46.5) | |
| Age, y | |||
| ≤50 | 385 (18.4) | 999 (20.8) | 2.4 (0.38 to 4.4) |
| 51-60 | 649 (31.0) | 1475 (30.7) | 0.3 (−2.1 to 2.7) |
| 61-70 | 562 (26.9) | 1286 (26.7) | 0.2 (−2.1 to 2.5) |
| >70 | 495 (23.7) | 1046 (21.8) | 1.9 (−0.3 to 4.1) |
| Sex | |||
| Male | 1453 (69.5) | 3080 (64.0) | 5.5 (3.1 to 7.9) |
| Female | 638 (30.5) | 1792 (36.0) | |
| Year of diagnosis | |||
| 2004-2006 | 602 (28.8) | 923 (19.2) | 9.6 (7.4 to 11.8) |
| 2007-2009 | 775 (37.1) | 1581 (32.9) | 4.2 (1.7 to 6.7) |
| 2010-2012 | 714 (34.2) | 2305 (47.9) | 13.7 (11.2 to 16.2) |
| Distance, miles | |||
| <10 | 1141 (54.6) | 1828 (38.0) | 16.6 (14.1 to 19.1) |
| 10-19 | 364 (17.4) | 945 (19.7) | 2.3 (0.3 to 4.3) |
| 20-29 | 188 (9.0) | 500 (10.4) | 1.4 (−0.1 to 2.9) |
| ≥30 | 348 (16.6) | 1440 (29.9) | 13.3 (11.2 to 15.4) |
| Unknown | 50 (2.4) | 96 (2.0) | 0.4 (−0.3 to 1.2) |
| Facility | |||
| Academic | 779 (37.3) | 2913 (60.6) | 23.2 (20.8 to 25.8) |
| Comprehensive community cancer program | 875 (41.9) | 1198 (24.9) | 17.0 (14.6 to 19.4) |
| Community or integrated network cancer program | 382 (18.3) | 531 (11.0) | 7.3 (5.4 to 9.2) |
| Unknown | 55 (2.6) | 167 (3.5) | 0.9 (0.0 to 1.8) |
| Comorbidity index | |||
| 1 | 1746 (83.5) | 3707 (77.1) | 6.4 (4.4 to 8.4) |
| 2 | 255 (12.2) | 874 (18.2) | 6.0 (4.2 to 7.8) |
| 3 | 90 (4.3) | 228 (4.7) | 0.4 (−0.7 to 1.5) |
| Clinical T stage | |||
| cT1-cT2 | 474 (22.7) | 1504 (31.3) | 8.6 (6.4 to 10.8) |
| cT3-cT4a | 1581 (75.6) | 3246 (67.5) | 8.1 (5.8 to 10.4) |
| Unknown | 36 (1.7) | 59 (1.2) | 0.5 (−0.1 to 1.1) |
| Clinical N stage | |||
| cN0-cN1 | 971 (46.4) | 2795 (58.1) | 11.7 (9.1 to 14.3) |
| cN2a-cN2c | 1079 (51.6) | 1925 (40.0) | 11.6 (9.0 to 14.2) |
| Unknown | 41 (2.0) | 89 (1.9) | 0.5 (−0.1 to 1.13) |
| Pathologic stage group | |||
| I-II | NA | 248 (5.2) | NA |
| III-IVA | 3834 (79.7) | ||
| Unknown | 727 (15.1) | ||
| Pathologic T stage | |||
| pT1-pT2 | NA | 1578 (32.8) | NA |
| pT3-pT4a | 2615 (54.4) | ||
| Unknown | 616 (12.8) | ||
| Pathologic N stage | |||
| pN0-pN1 | NA | 2076 (43.2) | NA |
| pN2a-pN3 | 2032 (42.3) | ||
| Unknown | 701 (14.6) | ||
| Chemotherapy | |||
| Yes | 2091 (100.0) | 2475 (51.5) | 48.5 (47.1 to 49.9) |
| No | 0 (0.0) | 2246 (46.7) | 46.7 (45.3 to 48.1) |
| Unknown | 0 (0.0) | 88 (1.8) | 1.8 (1.4 to 2.2) |
| Site | |||
| Oral tongue | 985 (47.0) | 1718 (35.7) | 11.3 (8.8 to 13.8) |
| Other mouth | 1106 (52.9) | 3091 (64.3) | |
Abbreviations: CRT, chemoradiotherapy; NA, not applicable; OCSCC, oral cavity squamous cell carcinoma; S+PORT, surgery and postoperative radiotherapy.
a
Data are presented as number (percentage) of patients unless otherwise indicated.